Physician profile
Pawan Rawal
NPI 1255659009
$13,497.20
in general payments reported to CMS, 2019-2025
51 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $1,340 · 2021: $1,421 · 2022: $2,428 · 2023: $3,609 · 2024: $2,788 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,292 · Honoraria: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,292.05 |
| Honoraria | $1,575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Natus Medical Incorporated | $1,575.00 | 2023 | |
| Supernus Pharmaceuticals, INC. | $1,330.24 | 2019-2021 | |
| Ucb, INC. | $1,191.52 | 2019-2025 | Rystiggo, Nayzilam, Fintepla |
| Alexion Pharmaceuticals, INC. | $913.42 | 2020-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $860.95 | 2020-2025 | |
| Abbvie INC. | $701.83 | 2021-2025 | |
| Sk Life Science, INC. | $685.03 | 2020-2025 | |
| Lundbeck LLC | $579.85 | 2022-2025 | Vyepti |
| Pfizer INC. | $572.00 | 2023-2025 | |
| Eisai INC. | $497.94 | 2019-2025 | |
| Horizon Therapeutics Plc | $453.02 | 2022-2023 | Uplizna |
| Argenx US, INC. | $384.04 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $346.26 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Sunovion Pharmaceuticals INC. | $264.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $253.60 | 2021-2025 | Wainua |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $242.94 | 2021-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Amgen INC. | $202.96 | 2019-2025 | Uplizna |
| Allergan, INC. | $198.25 | 2020-2021 | |
| Neurelis, INC. | $189.09 | 2020-2025 | Valtoco |
| Biogen, INC. | $183.02 | 2021-2024 | Tysabri |
| Biohaven Pharmaceutical Holding Company Ltd. | $168.43 | 2022 | |
| Csl Behring | $164.04 | 2021-2025 | Hizentra |
| Emd Serono, INC. | $136.55 | 2021-2023 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $132.84 | 2022-2025 | Hyqvia |
| Tanabe Pharma America, INC. | $130.65 | 2021-2022 | |
| Tg Therapeutics, INC. | $123.17 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $120.70 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $120.30 | 2021-2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $107.99 | 2023-2025 | Nuedexta, Rexulti |
| Sumitomo Pharma America, INC. | $81.44 | 2023-2024 | Aptiom |
| Banner Life Sciences, LLC | $71.53 | 2022 | |
| Lilly USA, LLC | $67.63 | 2024-2025 | Kisunla, Amyvid |
| C2n Diagnostics, LLC | $48.96 | 2025 | Precivityad2 |
| Biohaven Pharmaceuticals, INC. | $37.25 | 2021 | |
| Acadia Pharmaceuticals INC | $33.91 | 2024 | Nuplazid |
| Janssen Biotech, INC. | $31.73 | 2025 | |
| Celgene Corporation | $31.55 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $25.87 | 2023 | Firdapse |
| Jazz Pharmaceuticals INC. | $25.12 | 2023 | |
| Daiichi Sankyo INC. | $24.10 | 2019 | |
| Mdd US Operations, LLC | $22.77 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.49 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.91 | 2025 | Amvuttra |
| Axsome Therapeutics, INC. | $19.86 | 2025 | Symbravo |
| Ge Healthcare | $18.15 | 2021 | |
| Livanova USA, INC. | $16.86 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Insightec,INC | $15.60 | 2025 | Exablate |
| Ultragenyx Pharmaceutical INC. | $15.06 | 2024 | Dojolvi |
| Upsher-Smith Laboratories LLC | $13.70 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pawan Rawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.